Developer of small vascular grafts synthetic vascular grafts used to replace or bypass damaged or diseased arteries. Grafts are manufactured using Corvita's a proprietary polycarbonate urethane material which can closely replicate the strength and elasticity of human arteries. The product line, called Corvita Grafts, includes: (1) the Peripheral Graft, used to replace diseased arteries primarily in the leg, (2) the AV Access Graft, an arterial to venous graft implanted in the arm to draw and return blood during hemodialysis, and (3) the Endovascular Graft, introduced via minimally invasive surgical techniques and designed to treat damaged arteries. U.S. clinical trials of the Peripheral Graft began in September 1992 a request for pre-market approval (PMA) will be filed in mid-1995. Clinical trials of the AV Access Graft began in the U.S. in March 1994 and Corvita expects to file a PMA in late 1995. Clinical testing of the Endovascular Graft is slated to begin in mid-1995.